Bribery, Corruption and the American Health Care Way – Image for illustrative purposes only (Image credits: Pixabay)
Concerns over fraud in American healthcare have resurfaced amid broader discussions of corruption across government sectors. Officials at the Department of Health and Human Services highlighted schemes involving Medicaid and hospice operations, yet these cases represent only a fraction of longstanding issues. Providers have long exploited public programs like Medicare and Medicaid, while major corporations face lighter repercussions through settlements rather than criminal trials.
The disparity underscores a system where scale determines consequences, with small-scale operators bearing the brunt of enforcement while industry leaders pay penalties that barely dent their profits.
Small-Scale Schemes Meet Harsh Penalties
Individuals caught in straightforward fraud schemes often faced severe punishments. In 2011, a Florida man convicted of defrauding Medicare of tens of millions received a 50-year prison sentence. Thousands of similar cases involved providers billing for fictitious patients, leading to convictions and lengthy incarcerations.
These prosecutions targeted amateurs who lacked the resources to mount prolonged defenses. Enforcement agencies pursued them aggressively, resulting in jail time that served as a deterrent for low-level actors. However, such outcomes contrasted sharply with the treatment reserved for larger entities.
Corporate Settlements as the Norm
Major pharmaceutical companies routinely resolved allegations through multimillion-dollar settlements rather than court battles. GlaxoSmithKline paid $3 billion for off-label drug promotion, while Pfizer and Johnson & Johnson each exceeded $2 billion in similar cases. Hospital Corporation of America settled for $1.7 billion in the 1990s under then-CEO Rick Scott.
These resolutions allowed companies to avoid admissions of wrongdoing and continue operations. Whistleblower lawsuits under the False Claims Act became a pathway for insiders to expose misconduct, though executives rarely faced personal liability. The pattern persisted into recent years, with CVS/Aetna settling an upcoding case for $117 million after allegedly generating billions in extra revenue.
Medicare Advantage: A Modern Fraud Hotspot
Risk adjustment in Medicare Advantage plans emerged as a prime area for exploitation. Insurers upcoded patient diagnoses to inflate risk adjustment factors, securing higher payments without providing corresponding care. A Wall Street Journal investigation revealed $50 billion in such overpayments, with many patients receiving no additional treatment.
UnitedHealth Group’s acquisition of a Los Angeles medical group in 2017 led to a rapid rise in risk scores from 1.0 to 1.5, raising questions about genuine health declines. The Centers for Medicare & Medicaid Services attempted to recover overpayments through audits, but a 2025 court ruling limited fines to audited cases only. This decision protected plans from broader accountability, despite evidence of widespread upcoding.
| Company | Settlement Amount | Allegation |
|---|---|---|
| GlaxoSmithKline | $3 billion | Off-label promotion |
| Pfizer | Over $2 billion | Off-label promotion |
| CVS/Aetna | $117 million | Upcoding |
| Practice Fusion | $154 million | Drug promotion influence |
Reform Proposals to Curb Incentives
Experts advocate shifting away from fee-for-service models that encourage volume over value. Annual capitation payments to primary care providers could align incentives, prompting oversight of subcontractors to prevent fraud. Accountable care organizations recently flagged excessive wound care costs attributed to them, demonstrating potential benefits.
Broader changes include government-financed flat-fee systems with salaried staff and nonprofit structures, reducing profit motives. Centene once billed for the same Medicaid recipient across two states, highlighting persistent gaps. A cultural emphasis on patient care over revenue, reinforced by ethical oaths, remains essential.
Stakeholders in healthcare must prioritize transparency and advocate for processes that make fraud difficult. While political will for executive prosecutions appears limited, structural reforms offer a path to diminish corruption’s hold.
